Breakthrough Blood Test Detects Brain Cancer with Over 90% Accuracy
Scientists have developed a groundbreaking new blood test that can detect aggressive brain tumours with more than 90 per cent accuracy. This innovative diagnostic tool also monitors the progression of glioblastomas, offering a significant advancement in cancer detection and management.
University of Manchester Leads Collaborative Research
The research was led by the University of Manchester in collaboration with Danish scientific teams. The test works by identifying two specific blood proteins that are associated with brain tumours and their response to treatment. This method provides a stable and robust detection system, even as tumours evolve over time.
Less Invasive Alternative to Current Methods
Currently, diagnosing brain cancer often requires surgical biopsies and extensive MRI scans, which can be invasive, time-consuming, and uncomfortable for patients. The new blood test offers a less invasive and potentially faster diagnostic alternative. It can indicate when treatment is not working or when cancer has returned earlier than existing methods, allowing for quicker medical interventions.
Clinical Trials and Future NHS Integration
Clinical trials for the blood test are currently underway across various sites in the UK and internationally. Researchers are hopeful that the test could be integrated into the National Health Service within the next decade. This integration aims to facilitate earlier diagnosis and improve patient outcomes by enabling more timely and effective treatment plans.
Implications for Brain Cancer Patients
The development of this blood test represents a significant step forward in the fight against brain cancer. By providing a reliable, non-invasive option for detection and monitoring, it has the potential to transform patient care and enhance survival rates. The test's ability to accurately track tumour progression and treatment response could lead to more personalised and effective cancer therapies in the future.
